Financial Statements Company Balance Sheet at 31December AstraZeneca PLC 2018 2017 Notes $m $m Fixed assets Fixed asset investments 1 33,244 31,482 Current assets Debtors other 11 Debtors amounts owed by Group undertakings 4,466 7,995 4,466 8,006 Creditors: Amounts falling due within one year Non-trade creditors 2 383 325 Interest-bearing loans and borrowings 3 999 1,397 1,382 1,722 Net current assets 3,084 6,284 Total assets less current liabilities 36,328 37,766 Creditors: Amounts falling due after more than one year Amounts owed to Group undertakings 3 283 283 Interest-bearing loans and borrowings 3 17,013 15,197 17,296 15,480 Net assets 19,032 22,286 Capital and reserves Called-up share capital 4 317 317 Share premium account 4,427 4,393 Capital redemption reserve 153 153 Other reserves 2,533 2,549 Profit and loss account 11,602 14,874 Shareholders funds 19,032 22,286 $m means millions of US dollars.
The Companys profit for the year was $266m 2017: $3,109m.
The Company Financial Statements from page 205 to 209 were approved by the Board and were signed on its behalf by Pascal Soriot Marc Dunoyer Director Director 14February 2019 Companys registered number 02723534 AstraZeneca Annual Report & Form 20-F Information 2018 Company Statements 205 Company Statement of Changes in Equity for the year ended 31December Share Capital Share premium redemption Other Profitand Total capital account reserve reserves lossaccount equity $m $m $m $m $m $m At 1January 2017 316 4,351 153 2,583 15,307 22,710 Total comprehensive income for the period Profit for the period 3,109 3,109 Amortisation of loss on cash flow hedge 1 1 Total comprehensive income for the period 3,110 3,110 Transactions with owners, recorded directly in equity Dividends 3,543 3,543 Capital contributions for share-based payments 34 34 Issue of Ordinary Shares 1 42 43 Total contributions by and distributions to owners 1 42 34 3,543 3,534 At 31December 2017 317 4,393 153 2,549 14,874 22,286 Total comprehensive income for the period Profit for the period 266 266 Amortisation of loss on cash flow hedge 1 1 Total comprehensive income for the period 267 267 Transactions with owners, recorded directly in equity Dividends 3,539 3,539 Capital contributions for share-based payments 16 16 Issue of Ordinary Shares 34 34 Total contributions by and distributions to owners 34 16 3,539 3,521 At 31December 2018 317 4,427 153 2,533 11,602 19,032 At 31 December 2018, $11,602m 2017: $14,874m of the Profit and loss account reserve was available for distribution, subject to filing these Financial Statements with Companies House.
Included in Other reserves is a special reserve of $157m 2017: $157m, arising on the redenomination of share capital in 1999.
The other reserves arose from the cancellation of share premium by the Company in 1993.
Included within Other reserves at 31 December 2018 is $692m 2017: $708m in respect of cumulative share-based payment awards.
206 AstraZeneca Annual Report & Form 20-F Information 2018 Financial Statements
